Cargando…

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer

Gilteritinib is a multitarget tyrosine kinase inhibitor (TKI), approved for the treatment of FLT3‐mutant acute myeloid leukemia, with a broad range of activity against several tyrosine kinases including anaplastic lymphoma kinase (ALK). This study investigated the efficacy of gilteritinib against AL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ando, Chihiro, Ichihara, Eiki, Nishi, Tatsuya, Morita, Ayako, Hara, Naofumi, Takada, Kenji, Nakasuka, Takamasa, Watanabe, Hiromi, Kano, Hirohisa, Nishii, Kazuya, Makimoto, Go, Kondo, Takumi, Ninomiya, Kiichiro, Fujii, Masanori, Kubo, Toshio, Ohashi, Kadoaki, Matsuoka, Ken‐ichi, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637052/ https://www.ncbi.nlm.nih.gov/pubmed/37715310 http://dx.doi.org/10.1111/cas.15958

Ejemplares similares

Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
por: Nishii, Kazuya, et al.
Publicado: (2021)

CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Hara, Naofumi, et al.
Publicado: (2023)

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
por: Watanabe, Hiromi, et al.
Publicado: (2021)

Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
por: Ichihara, Eiki, et al.
Publicado: (2018)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)

Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan
por: Ando, Eri, et al.
Publicado: (2021)

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
por: Makimoto, Go, et al.
Publicado: (2022)

Identification of targetable kinases in idiopathic pulmonary fibrosis
por: Higo, Hisao, et al.
Publicado: (2022)

Massive hemoptysis in a post-operative patient with recurrent lung cancer successfully treated by the combination therapy of Endobronchial Watanabe Spigot and bronchial artery embolization
por: Taoka, Masataka, et al.
Publicado: (2022)

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
por: Watanabe, Hiromi, et al.
Publicado: (2017)

A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages
por: Watanabe, Hiromi, et al.
Publicado: (2019)

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
por: Makimoto, Go, et al.
Publicado: (2019)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease
por: Okawa, Sachi, et al.
Publicado: (2021)

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
por: Itano, Junko, et al.
Publicado: (2019)

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status
por: Kano, Hirohisa, et al.
Publicado: (2020)

Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab
por: Senoo, Satoru, et al.
Publicado: (2018)

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
por: Kudo, Kenichiro, et al.
Publicado: (2017)

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
por: Hotta, Katsuyuki, et al.
Publicado: (2011)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
por: Harada, Daijiro, et al.
Publicado: (2021)

Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography
por: Minami, Daisuke, et al.
Publicado: (2016)

Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation
por: Morichika, Daisuke, et al.
Publicado: (2016)

Treatment-Related Death in Patients with Small-Cell Lung Cancer in Phase III Trials over the Last Two Decades
por: Ochi, Nobuaki, et al.
Publicado: (2012)

Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review
por: Hotta, Katsuyuki, et al.
Publicado: (2015)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

Chemo-preventive effects and antitumorigenic mechanisms of beer and nonalcoholic beer toward 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) - induced lung tumorigenesis in A/J mice
por: Takata, Jun, et al.
Publicado: (2023)

Managing Lung Cancer with Comorbid Interstitial Pneumonia
por: Ichihara, Eiki, et al.
Publicado: (2019)

A case of axillary lymphadenitis caused by Mycobacterium intracellulare in an immunocompetent patient
por: Itano, Junko, et al.
Publicado: (2019)

Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review
por: Makimoto, Go, et al.
Publicado: (2019)

The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy
por: Hida, Toyoaki, et al.
Publicado: (2016)

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non–Small-Cell Lung Cancer: AF-001JP
por: Tamura, Tomohide, et al.
Publicado: (2017)

Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model
por: Minami, Daisuke, et al.
Publicado: (2015)

Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia
por: Makimoto, Go, et al.
Publicado: (2022)

Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results
por: Oze, Isao, et al.
Publicado: (2009)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

Pneumocystis Pneumonia Concomitant with Ectopic ACTH Syndrome Caused by a Large Cell Neuroendocrine Carcinoma of the Thymus
por: Oda, Naohiro, et al.
Publicado: (2017)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o4i1m1ob53fesfi3qts58epjiq